alexa Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study
ISSN: 2161-0932

Gynecology & Obstetrics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study

Ahmed S El-Halwagy*, Adel A Al-Gergawy, Abdelghafar S Dawood and Ayman Shehata

Department of Obstetrics and Gynecology, Faculty of medicine, Tanta University, Egypt

*Corresponding Author:
Ahmed S El-Halwagy
Lecturer, Department of Obstetrics and Gynecology
Faculty of medicine, Tanta University, Egypt
Tel: 00201202224924;

Received December 21, 2016; Accepted date: January 12, 2017; Published date: January 17, 2017

Citation: El-Halwagy AS, Al-Gergawy AA, Dawood AS, Shehata A (2017) Reduction of Postoperative Adhesions after Laparoscopic Surgery for Endometriosis by Using a Novel Anti-Fibrotic Drug Pirfenidone: A Randomized Double Blind Study. Gynecol Obstet (Sunnyvale) 7:422. doi: 10.4172/2161-0932.1000422

Copyright: © 2017 El-Halwagy AS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Introduction: This study was done to insight the effect of the novel anti-fibrotic drug Pirfenidone in the prevention of postoperative endometriosis induced adhesions. Patients and methods: 210 patients were enrolled and randomly allocated into 2 groups according to sequence of computer-generated block-random numbers. Each group included 105 patients. This prospective randomized double blind controlled study was conducted at Tanta University Hospital between August 2013 and May 2016. In group A (study group) the patients after the initial laparoscopic management received Pirfenidone 200 mg (pirfinex) tablets in a dose of 3 tablets tds i.e. 1800 mg daily for 6 months while in group B (control group) the patients after the initial laparoscopy received placebo starch tablets 3 tablets tds also for 6 months. The patients in both study groups were subjected to 2nd look laparoscopy after 6 months from the initial procedure. The primary outcome measure of the study was the difference in the AFS scoring between the study groups during the second look laparoscopies. Secondary outcome measure was the difference between both groups regarding the rate of pregnancy before the second look. Results: On comparing the American Fertility Society score on 2nd look laparoscopy between both groups a statistically significant lower score was found in the study group A when compared to the control group B (P=0.019). 95% CI for difference: (-8.00; -0.73). The pregnancy rate before the 2nd look laparoscopy was 39.3% in group A and 31% in group B and this difference is statistically non-significant (P=0.215). Conclusion: Although that from the results of this study we can conclude that Pirfenidone (Pirfenix) is an effective drug to be used in reduction of the postoperative endometriosis provoked adhesions, the actual benefit of pirfenidone is very moderate (no difference in pregnancy rates). Pirfenidone provides minor clinical added value. The use of pirfenidone should not be recommended since its use is associated with potential adverse events (side effects). Use of pirfenidone necessitates regular monitoring of tolerability and liver enzymes. The most commonly reported adverse events were gastrointestinal disorders (nausea, dyspepsia and diarrhoea), rash, photosensitivity and fatigue. Pirfenidone is an immunosuppressant. Therefore, its use should be limited to proven indications.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

1-702-714-7001Extn: 9042

General Science

Andrea Jason

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001Extn: 9042

© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version